Abstract: Methods and server systems for computing fraud risk scores for various merchants associated with an acquirer described herein. The method performed by a server system includes accessing merchant-related transaction data including merchant-related transaction indicators associated with a merchant from a transaction database. Method includes generating a merchant-related transaction features based on the merchant-related indicators. Method includes generating via risk prediction models, for a payment transaction with the merchant, merchant health and compliance risk scores, merchant terminal risk scores, merchant chargeback risk scores, and merchant activity risk scores based on the merchant-related transaction features. Method includes facilitating transmission of a notification message to an acquirer server associated with the merchant.

Abstract: The present invention relates to an improved process for the preparation of a compound of Formula (1), The invention also provides improved processes for the preparation of intermediates used in the synthesis of Formula (1). The compound of Formula (1) is used in the synthesis of Semaglutide.

Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.

Abstract: The present provides a simple, convenient and time-efficient process for the preparation of propofol. Particularly, the present invention provides an improved process for the preparation of propofol using a heterocyclic base for the decarboxylation reaction. The present invention provides a time-efficient process for the preparation of propofol with high yield and purity.

Abstract: The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PG1 may be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC.

Abstract: Disclosed are techniques for wireless communication. In an aspect, a first station (STA) may receive a first packet from a second STA at a first time-of-arrival of the first packet. The first STA may activate a strobe signal to store first sensor data at the first time-of-arrival, wherein the first sensor data corresponds to a sensor output of one or more sensors of the first STA at the first time-of-arrival, wherein the one or more sensors include an accelerometer, a gyroscope, a magnetometer, or any combination thereof.

Abstract: This disclosure provides methods, devices, and systems for minimizing ranging errors resulting from clock drift and/or frequency offsets between wireless communication devices such as a responder device and an initiator device. In various implementations, the responder device receives a request for a ranging operation from the initiator device. The responder device determines whether its temperature exceeds a threshold. When the responder device's temperature exceeds the threshold, the responder device determines a time period after which the responder device's temperature is expected to decrease below the threshold. The responder device transmits a response frame indicating the responder device's temperature and the determined time period. In some instances, the determination that the responder device's temperature exceeds the threshold indicates that ranging errors resulting from clock drift and/or frequency offsets between the responder device and the initiator device are greater than an amount.

Abstract: The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer.

Abstract: The present disclosure provides an apparatus and method for sharing content. A method provided in the present disclosure comprises receiving a message to request to join a content sharing group from a second device while a third device included in the content sharing group transmits first content shared in the content sharing group to a fourth device included in the content sharing group, adding the second device to the content sharing group, and permitting the second device to access the first content.

Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.

Abstract: The present invention relates to a process for the purification of compound of formula II, wherein X may be independently selected from trifluoroacetic acid, hydrochloric acid, hydrobromic acid, p-toluene sulfonic acid and phosphoric acid; its isolation as solid and use for the preparation of carfilzomib.

Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.

Abstract: The present disclosure provides an apparatus and method for sharing content. A method provided in the present disclosure comprises receiving a message to request to join a content sharing group from a second device while a third device included in the content sharing group transmits first content shared in the content sharing group to a fourth device included in the content sharing group, adding the second device to the content sharing group, and permitting the second device to access the first content.

Abstract: The invention relates to a process for the preparation of ribociclib of formula V or its salts. The invention provides novel crystalline forms of ribociclib succinate and ribociclib trifluoroacetate. The present invention also relates to pharmaceutical compositions comprising a crystalline form of ribociclib succinate and at least a pharmaceutically acceptable carrier. It further relates to the use of such compositions in the treatment of cancer.

Abstract: The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-?-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.

Abstract: The present invention relates to an improved process for the preparation of a compound of formula (I), wherein PG1 may be independently selected from tert-butyloxycarbonyl (Boc), phthaloyl, 9-fluorenylmethyloxycarbonyl (Fmoc), triphenylmethyl (Trityl), carboxybenzyl (Cbz), trifluoroacetyl, benzyl (Bn), benzylidene, methanesulfonyl (Mesyl), toluene sulfonyl (Tosyl) or acyl; its isolation as solid and use for the preparation of the compound of formula (IV), in particular the compound of formula (IV) i.e. [(1R)-3-methyl-1[[(2S)-1-oxo-3-phenyl-2-[(pyrazinylcarbonyl) amino]propyl]amino]butyl] boronic acid with more than 99.95% chiral purity, as measured by HPLC.

Abstract: The present application provides an improved process for the preparation of sugammadex by reacting a salt of 3-mercapto propionic acid with 6-per-deoxy-6-per-halo-?-cyclodextrin in a suitable organic solvent. This application also provides crystalline form of a salt of 3-mercapto propionic acid, preferably di sodium salt of 3-mercapto propionic acid and its use for the preparation of sugammadex, whereas formula (I) shows the sodium salt of sugammadex.

Abstract: The present application provides an improved process for the preparation of sugammadex which comprises the halogenation of ?-cyclodextrin in a suitable organic solvent to give 6-per-deoxy-6-per-halo-?-cyclodextrin, wherein halo is bromo or chloro, reacting the halogenated ?-cyclodextrin with 3-mercaptopropionic acid in the presence of alkoxide base to obtain sugammadex of formula I. This application also provides isolation of 6-per-deoxy-6-per-chloro-?-cyclodextrin as a crystalline compound and its use for the preparation of sugammadex of formula (I).

Abstract: The present application provides crystalline forms of 6-per-deoxy-6-per-chloro-?-cyclodextrin, and polymorphs thereof. The present application also provides methods for preparing said polymorphs by dissolving 6-per-deoxy-6-per-chloro-?-cyclodextrin in dimethylformamide and using an anti-solvent of a water/alcohol mixture.

Abstract: The present invention relates to the polymorphic forms of Belinostat. The invention also relates to the process for the preparation of the polymorphic forms of Belinostat. This invention further relates to pharmaceutical composition of said polymorphic forms of Belinostat and use thereof in the treatment of a patient in need thereof.